These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2295222)

  • 21. Pharmacokinetics of ticarcillin in man.
    Davies BE; Humphrey MJ; Langley PF; Lees L; Legg B; Wadds GA
    Eur J Clin Pharmacol; 1982; 23(2):167-72. PubMed ID: 7140806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.
    Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.
    Alván G; Beermann B; Hjelte L; Lind M; Lindholm A; Strandvik B
    Clin Pharmacol Ther; 1988 Oct; 44(4):436-41. PubMed ID: 3168395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep.
    Errecalde JO; Lanusse CE; Mestorino ON; Landoni MF; Soraci AL
    Zentralbl Veterinarmed A; 1991 May; 38(4):255-60. PubMed ID: 1907783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic comparison of mezlocillin and ticarcillin.
    Deeter RG; Barriere SL; Fekety R
    Clin Pharm; 1988 May; 7(5):380-4. PubMed ID: 3383544
    [No Abstract]   [Full Text] [Related]  

  • 26. Ticarcillin plus clavulanic acid: pharmacokinetic study in renal failure.
    Stathakis C; Bakounsli I; Iatrou C; Boletis J; Kosmidis J
    Chemioterapia; 1987 Jun; 6(2 Suppl):265-7. PubMed ID: 3509408
    [No Abstract]   [Full Text] [Related]  

  • 27. Biliary elimination of ticarcillin plus clavulanic acid (Claventin): experimental and clinical study.
    Brogard JM; Jehl F; Blickle JF; Adloff M; Dorner M; Montell H
    Int J Clin Pharmacol Ther Toxicol; 1989 Mar; 27(3):135-44. PubMed ID: 2722309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of ticarcillin/clavulanate into cartilage.
    Meier H; Adam D; Heilmann HD
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():101-5. PubMed ID: 2606811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime pharmacokinetics in cystic fibrosis.
    Hamelin BA; Moore N; Knupp CA; Ruel M; Vallée F; LeBel M
    Pharmacotherapy; 1993; 13(5):465-70. PubMed ID: 8247913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of the combination of ticarcillin with clavulanic acid in renal insufficiency.
    Dalet F; Amado E; Cabrera E; Donate T; del Rio G
    J Antimicrob Chemother; 1986 May; 17 Suppl C():57-64. PubMed ID: 3722047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacokinetics of ticarcillin in patients with normal and impaired renal function (author's transl)].
    Höffler D; Dalhoff A; Koeppe P
    Dtsch Med Wochenschr; 1978 Jun; 103(22):931-5. PubMed ID: 350535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].
    Guggenbichler JP; Pillwein K; Schabel F; Rohrer R
    Padiatr Padol; 1981; 16(4):393-402. PubMed ID: 7301388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim.
    Hutabarat RM; Unadkat JD; Sahajwalla C; McNamara S; Ramsey B; Smith AL
    Clin Pharmacol Ther; 1991 Apr; 49(4):402-9. PubMed ID: 2015729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of ticarcillin in the dog.
    Tilmant L; Brown MP; Gronwall RR
    Am J Vet Res; 1985 Feb; 46(2):479-81. PubMed ID: 3922261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients.
    Bosso JA; Townsend PL; Herbst JJ; Matsen JM
    Antimicrob Agents Chemother; 1985 Dec; 28(6):829-31. PubMed ID: 4083865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azlocillin pharmacokinetics in patients with cystic fibrosis.
    Bosso JA; Saxon BA; Herbst JJ; Matsen JM
    Antimicrob Agents Chemother; 1984 May; 25(5):630-2. PubMed ID: 6732230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasma level of dibekacin in children with mucoviscidosis. Comparison with a control population].
    Loeuille GA; Cournol R; Delnatte J; Martin G
    Ann Pediatr (Paris); 1987 Nov; 34(9):713-7. PubMed ID: 3426082
    [No Abstract]   [Full Text] [Related]  

  • 39. High-pressure liquid chromatographic assays for ticarcillin in serum and urine.
    Kwan RH; MacLeod SM; Spino M; Teare FW
    J Pharm Sci; 1982 Oct; 71(10):1118-21. PubMed ID: 7143209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.
    Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC
    J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.